Thermo Fisher Scientific CD19 Monoclonal Antibody (6OMP31), Alexa Fluor 488, eBioscience

Applications

Tested Dilution

Publications

Western Blot (WB)

0.5 µg/mL

-

Immunohistochemistry (IHC)

-

View 6 publications 6 publications

Immunohistochemistry (Paraffin) (IHC (P))

10 µg/mL

View 1 publication 1 publication

Immunohistochemistry (Frozen) (IHC (F))

10 µg/mL

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse, Rat

Published species

Human, Mouse

Host/Isotype

Rat / IgG2a, kappa

Recommended Isotype Control

Rat IgG2a kappa Isotype Control (eBR2a), Alexa Fluor™ 488, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

6OMP31

Conjugate

Alexa Fluor™ 488 Alexa Fluor™ 488 Alexa Fluor™ 488

View additional formats

• Unconjugated
• Biotin
• Request custom conjugation

Excitation/Emission Max

499/520 nm View spectra

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2637166

Product Specific Information

Description: The 6OMP31 monoclonal antibody reacts with human, mouse, and rat CD19. CD19 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 was first identified as the B4 antigen of human B lymphocytes using the anti-B4 monoclonal. It is expressed by B cells during all stages of development, except on terminally differentiated plasma cells, and on follicular dendritic cells. CD19 acts primarily as a B cell co-receptor and together with CD21, CD81, Leu13, and MHC class II forms a multi-molecular complex that associates with the BCR. CD19 plays a role in the development, activation, differentiation, and proliferation of B cells. CD19 deficiency leads to an overall impaired humoral immune response. Mutations in CD19 have been associated with severe immunodeficiency syndromes. Although it is unclear whether CD19 contributes directly to B cell carcinogenesis, it is expressed on most B cell tumors, such as acute lymphoblastic leukemias and B cell lymphomas. The use of CD19 monoclonal antibodies for therapies against lymphoma, leukemia and autoimmune disorders are currently being explored.

Applications Reported: This 6OMP31 antibody has been reported for use in immunohistochemical staining of frozen tissue sections, and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections.

Applications Tested: This 6OMP31 antibody has been tested by immunohistochemistry of formalin-fixed paraffin embedded tissue using low or high pH antigen retrieval and can be used at less than or equal to 10 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Excitation: 488 nm; Emission: 519 nm; Laser: Blue Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains. CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias. Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.